Evidence map›Paper›PMID 28160073›Full record

ArticleParasitology research2017

Genistein improves schistosomiasis liver granuloma and fibrosis via dampening NF-kB signaling in mice.

Chunpeng Wan, Fen Jin, Youqin Du, Kang Yang, Liangliang Yao, Zhigang Mei, Weifeng Huang

Abstract read
PubMed Publisher
In one paragraph

Article in Parasitology research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Pathogenesis of Liver Fibrosis and Its TCM Therapeutic Perspectives.Evidence-based complementary and alternative medicine : eCAM · 2022
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Chunpeng WanDepartment of Microbiology and Immunology, Medical College, China Three Gorges University, Yichang, Hubei, 443002, China.
Fen JinDepartment of Microbiology and Immunology, Medical College, China Three Gorges University, Yichang, Hubei, 443002, China.
Youqin DuDepartment of Microbiology and Immunology, Medical College, China Three Gorges University, Yichang, Hubei, 443002, China.
Kang YangDepartment of Microbiology and Immunology, Medical College, China Three Gorges University, Yichang, Hubei, 443002, China.
Liangliang YaoAffiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi, 330006, People's Republic of China.
Zhigang MeiDepartment of Microbiology and Immunology, Medical College, China Three Gorges University, Yichang, Hubei, 443002, China. meizhigang@ctgu.edu.cn.
Weifeng HuangDepartment of Microbiology and Immunology, Medical College, China Three Gorges University, Yichang, Hubei, 443002, China. huangweifeng@ctgu.edu.cn.ORCID http://orcid.org/0000-0001-8546-1591
China Three Gorges University · CNAffiliated Hospital of Jiangxi University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In schistosomiasis, egg deposition in the liver contributes to the formation of hepatic granuloma and fibrosis, which are the most serious clinical pathological features. It has been proposed that activation of the nuclear factor kappa B (NF-κB) signaling pathways is closely associated with the development of hepatic granuloma and fibrosis. Genistein has been shown to inhibit the activity of NF-κB signaling pathways, which might be a potential agent to protect against Schistosoma japonicum egg-induced liver granuloma and fibrosis. In this study, liver granuloma and fibrosis were induced by infecting BALB/c mice with 18 ± 3 cercariae of S. japonicum. At the beginning of egg granuloma formation (early phase genistein treatment from 4 to 6 weeks after infection) or after the formation of liver fibrosis (late phase genistein treatment from 6 to 10 weeks after infection), the infected mice were injected with genistein (25, 50 mg/kg). The results revealed that genistein treatment significantly decreased the extent of hepatic granuloma and fibrosis in infected mice. The activity of NF-κB signaling declined sharply after the treatment with genistein, as evidenced by the inhibition of NF-κB-p65, phospho-NF-κB-p65, and phospo-IκB-α expressions, as well as the expression of IκB-α and the messenger RNA (mRNA) expression of inflammatory cytokines (MCP1, TNFα, IL1β, IL4, IL10) mediated by NF-κB signaling pathways in the early phase of the infection. Moreover, western blot and immunohistochemistry assays demonstrated that the contents of α-smooth muscle actin (α-SMA) and transforming growth factor-β were dramatically reduced in liver tissue under the treatment of genistein in the late phase of the infection. At the same time, the mRNA expression of MCP1, TNFα, and IL10 was inhibited markedly. These results provided evidence that genistein reduces S. japonicum egg-induced liver granuloma and fibrosis, at least partly due to decreased NF-κB signaling, and subsequently decreased MCP1, TNFα, and IL10 expressions. This implies that genistein can be a potential natural agent against schistosomiasis.

Indexed as

AnimalsAntiprotozoal AgentsCercariaChemokine CCL2Enzyme ActivationGenisteinGranulomaI-kappa B KinaseInterleukin-10LiverLiver CirrhosisMaleMiceMice, Inbred BALB CRNA, MessengerSchistosoma japonicumAntiprotozoal AgentsCcl2 protein, mouseChemokine CCL2Chuk protein, mouseGenisteinI-kappa B KinaseIL10 protein, mouseInterleukin-10Rela protein, mouseRNA, MessengerTranscription Factor RelATumor Necrosis Factor-alphaGenisteinLiver fibrosisLiver granulomaSchistosomiasis

Identifiers

PMID28160073
OpenAlexW2583401385

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.